n-(2-hydroxypropyl)methacrylamide has been researched along with alendronate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erez, R; Miller, K; Satchi-Fainaro, R; Segal, E; Shabat, D | 1 |
| Benayoun, L; Kopeček, J; Kopečková, P; Pan, H; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
| Benayoun, L; Eldar-Boock, A; Miller, K; Polyak, D; Satchi-Fainaro, R; Segal, E; Shaked, Y | 1 |
3 other study(ies) available for n-(2-hydroxypropyl)methacrylamide and alendronate
| Article | Year |
|---|---|
Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Neoplasms; Bridged-Ring Compounds; Cathepsin B; Cells, Cultured; Humans; Paclitaxel; Polymers; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Body Weight; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cyclohexanes; Humans; Male; Materials Testing; Mice; Mice, Inbred BALB C; Molecular Structure; O-(Chloroacetylcarbamoyl)fumagillol; Osteosarcoma; Polymers; Sesquiterpenes; Tissue Distribution | 2011 |
Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Topics: Acrylamides; Alendronate; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukocyte Count; Mice; Mice, Inbred BALB C; Paclitaxel | 2011 |